Posted January 26th, 2021 for Biodesix
Important New Findings Validate Testing Strategies That Support Decision Making for Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC)
BOULDER, CO, January 26, 2021 –Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings from these recent studies demonstrate that an individual patient’s immune profile can provide information to support treatment decisions for patients diagnosed with advanced non-small cell lung cancer (NSCLC).